Low-risk gestational trophoblastic neoplasia (GTN), defined as FIGO/WHO score 0–6, is
highly curable with an overall survival rate, which is approximately 100%. For most low-risk …

Introduction Gestational trophoblastic neoplasia (GTN) is a rare tumor that arises from
trophoblastic tissues with high remission rates after chemotherapy treatment. GTN can …

Objective To assess perinatal outcomes of first pregnancy after remission from gestational
trophoblastic neoplasia and the impact of the time between the end of chemotherapy and …

Objective There is no consensus regarding what should be the optimal single-agent
regimen in low-risk gestational trophoblastic neoplasia (LRGTN). we performed this network …

Objective To evaluate the efficacy of immunotherapy for GTN treatment after methotrexate-
resistance or in cases of multiresistant disease, through a systematic review, as well as to …

Abstract Background Actinomycin-D (Act-D) and Methotrexate (MTX) are both effective first-
line agents for low-risk gestational trophoblastic neoplasia (LRGTN) with no consensus …

Objective To evaluate the impact of periodic shortage of actinomycin-d (Act-d) in the
treatment of Brazilian patients with low-risk gestational trophoblastic neoplasia (GTN) after …

Gestational trophoblastic neoplasia (GTN) is a rare form of cancer with excellent cure rates,
in excess of 90% across all stages. 1–4 In large part, this is due to the high sensitivity of …

Objective To compare clinical outcomes of patients diagnosed with low-risk gestational
trophoblastic neoplasia (GTN) receiving intramuscular methotrexate 50 mg total dose/day …

Objective To assess whether the incidence and aggressiveness of molar pregnancy (MP)
and postmolar gestational trophoblastic neoplasia (GTN) changed during the COVID‐19 …